Commercial soft contact lenses engineered with zwitterionic silver nanoparticles for effectively treating microbial keratitis

[Display omitted] The introduction of various drugs onto commercial soft contact lenses (CLs) has emerged as a potentially effective strategy for treating microbial keratitis (MK) because drug-loaded CLs can maintain a controlled drug concentration which leaded to enhanced drug bioavailability and r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of colloid and interface science 2022-03, Vol.610, p.923-933
Main Authors: Ma, Li, Li, Kaijun, Xia, Jiali, Chen, Chaojian, Liu, Yuqi, Lang, Shiying, Yu, Ling, Liu, Gongyan
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Anti-Infective Agents
Contact lenses
Contact Lenses, Hydrophilic
Keratitis - drug therapy
Metal Nanoparticles
Microbial keratitis
Microbial Sensitivity Tests
Ophthalmology treatment
Rabbits
Silver
Sliver nanoparticles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The introduction of various drugs onto commercial soft contact lenses (CLs) has emerged as a potentially effective strategy for treating microbial keratitis (MK) because drug-loaded CLs can maintain a controlled drug concentration which leaded to enhanced drug bioavailability and reduced side effects in ocular tissues. In this study, silver nanoparticles modified with zwitterionic poly (carboxybetaine-co-dopamine methacrylamide) copolymer (PCBDA@AgNPs) as novel anti-infective therapeutics were prepared and firmly immobilized onto soft CLs through mussel-inspired surface chemistry. The obtained PCBDA@AgNPs coated CL (PCBDA@AgNPs-CL) remained the excellent transparency of commercial CLs and exhibited strong and broad-spectrum antimicrobial activities. We systematically explored the mechanism and found that the functional CLs can effectively inhibit the growth of microbial biofilms via a synergic “resist–kill–remove” strategy due to the zwitterionic surface and sustained release of silver ions. Significantly, in vitro cell cytotoxicity and in vivo subcutaneous implantation experiments proved the significant biosafety of PCBDA@AgNPs-CL. Furthermore, PCBDA@AgNPs-CL was successfully employed for the in vivo treatment of MK rabbit models, demonstrating excellent abilities to eradicate microbe-induced ocular infections and to prevent the destruction and irreversible structural alterations of corneal tissues. Collectively, PCBDA@AgNPs-CL is therefore a highly promising therapeutic device to significantly boost the efficacy for MK treatment.
ISSN:0021-9797
1095-7103
DOI:10.1016/j.jcis.2021.11.145